Human Fetuin-A
Produktdaten
Sample preparation
Serum should be separated within 3 hours after blood collection, measure or store at -20°C. Max. 3 freeze and thaw cycles.
Reference values
| range (g/l) | Mean (g/l) | SD (g/l) |
| 0.35 - 0.95 | 0.57 | 0.13 |
| Product name | Human Fetuin-A |
| Cat-Nr. | KT-800 |
| Range | 12.5 - 370 ng/ml |
| Sensitivity | 5.0 ng/ml |
| Incubation time | 3 hours |
| Sample volume | 10 µl (dilute 1:10.000) |
| Sample type | Serum |
| Species | Human |
| Tests | 96 |
| Method | ELISA |
Intended use
Fetuin-A synthesized in the liver is secreted into the blood stream and it is deposited, accumulated as a noncollagenous protein in mineralized bones and teeth. Fetuin-A acts as an important circulating inhibitor of ectopic calcification, a frequently seen complication in degenerative diseases. Low Fetuin-A level may be associated with higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis.
Human Fetuin-A represents a natural inhibitor of tyrosine kinase activity of the insulin receptor. Fetuin-A may play a significant role in regulating post-prandial glucose disposition, insulin sensitivity, weight gain, and fat accumulation and may be a novel therapeutic target in the treatment of type 2 diabetes, obesity, and other insulin-resistant conditions.
- Fetuin-A level (< 0.35 g/l) indicates a higher risk of cardiovascular calcification and increase mortality in ESRD-patients.
- Fetuin-A level (> 1.00 g/l) in elderly population, an independent risk factor of type II diabetes.
- Fetuin-A is an important predictor of death in acute myocardial infarction.
- Involved with the regulation of calcium metabolism and osteogenesis.
